On Oct 26, major Wall Street analysts update their ratings for $DexCom (DXCM.US)$, with price targets ranging from $85 to $115.
J.P. Morgan analyst Robbie Marcus downgrades to a hold rating, and adjusts the target price from $145 to $85.
BofA Securities analyst Travis Steed maintains with a buy rating.
Citi analyst Joanne Wuensch maintains with a buy rating.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $80 to $90.
Jefferies analyst Matthew Taylor maintains with a buy rating, and adjusts the target price from $160 to $100.
Furthermore, according to the comprehensive report, the opinions of $DexCom (DXCM.US)$'s main analysts recently are as follows:
DexCom has effectively bolstered investor confidence in its revenue target for 2025, which includes a minimal contribution from Stelo. It is anticipated that earnings estimates may rise in response to the company's return to double-digit revenue growth.
DexCom's third-quarter revenue outperformance was propelled by a record number of new patient initiations, yet earnings were affected by diminished gross margins. Momentum for DexCom is gathering as the year concludes, with a clear trajectory towards achieving at least a 15% year-over-year growth by 2025.
DexCom's third-quarter sales surpassed expectations, driven by a stronger than anticipated performance internationally, although the U.S. figures fell short relative to estimates. This discrepancy in the U.S. market is attributed to a decrease in new patient additions in the second quarter and anticipated effects from product mix. The company's guidance for sales and margins remains steady for 2024, in line with their targets for 2025.
Here are the latest investment ratings and price targets for $DexCom (DXCM.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
